Asia
Todos Medical Ltd. and Orot+ announced the enrollment of the first patient in the pre-commercial launch study of TM-B1 and TM-B2 in Europe.
60,000 sq. ft World-class Integrated R&D Facility at TICEL Bio Park to House 250 scientists
Teijin Pharma Limited announced that new topline results from a Phase II clinical trials, showing that TMX-049, which is being developed for the treatment of diabetic kidney disease in type 2 diabetes, achieved its primary endpoint for efficacy.
TLC178 shows potential as a treatment for sarcomas, with enhanced efficacy, reduced toxicity and decreased dosing frequency
Germany-based Evotec is partnering with Japan’s Takeda Pharmaceutical to develop at least five drug discovery programs across a broad range of indications.
Fujitsu and PeptiDream Leverage Quantum-Inspired Tech in Joint Research to Accelerate Drug Discovery
Fujitsu’s Quantum-Inspired Digital Annealer technology applied to drug discovery process to streamline the search for candidate compounds
Fujitsu Limited and PeptiDream Inc. has announced that they have agreed to initiate joint research and development in the area of peptide drug discovery, using Fujitsu’s Digital Annealer, which employs next-generation computing architecture to quickly solve combinatorial optimization problems.
Aiming to Expand Availability of Eribulin to Patients in India with Two Brands Halaven and Teceris
Eisai Co., Ltd. has announced that latest data on lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of sleep-wake disorders, including insomnia and Irregular Sleep-Wake Rhythm Disorder associated with Alzheimer’s disease/dementia will be presented at World Sleep Congress, from September 20 to 25 in Vancouver, Canada.
ASLAN Pharmaceuticals announced late-breaking topline data from a phase 2 study conducted in China testing varlitinib and capecitabine in second line BTC patients.
PRESS RELEASES